NewLimit triples valuation to $3B with $435M funding round
Coinbase CEO Brian Armstrong's longevity biotech startup is now worth $3.1 billion, before it has even tested its aging drug in humans.
Share
Add us on Google by Editorial Team Jun. 2, 2026Brian Armstrong wants to cure aging. And investors are writing very large checks to let him try.
NewLimit, the San Francisco-based biotech company co-founded by the Coinbase CEO, just closed a $435 million funding round that values the company at $3.1 billion in post-money terms. That’s roughly triple its previous valuation, which sat below $1 billion as recently as its Series B last year.
From crypto fortunes to cellular rejuvenation
Armstrong is best known for building Coinbase into one of the largest crypto exchanges on the planet. But since 2022, he’s been quietly building something in an entirely different domain: a company that wants to make human cells young again.
AdvertisementHe co-founded NewLimit alongside Blake Byers and Jacob Kimmel, the latter a former scientist at Calico, Alphabet’s longevity research lab. The premise is deceptively simple. As we age, our cells lose the ability to express genes the way they did when we were younger. NewLimit’s bet is that you can flip those switches back on.
The technical term is epigenetic reprogramming. Your DNA doesn’t change as you age, but the instructions your cells follow do. NewLimit is developing medicines that use transcription factors, essentially molecular tools, to restore youthful gene expression patterns in aged cells. The delivery mechanism relies on lipid nanoparticles, the same basic technology that made mRNA COVID vaccines possible.
The company’s initial targets are the liver, immune system, and vasculature. Here’s the thing: none of this has been tested in humans yet. NewLimit is targeting its first human clinical trials for 2027, meaning the $3.1 billion valuation is entirely based on preclinical work, human cell screens, and in vivo animal models.
The funding trajectory tells a story
NewLimit raised its seed and Series A rounds at valuations well below $1 billion. Then came a $130 million Series B in May 2025, led by Kleiner Perkins. Now, barely a year later, the company has raised more than three times that amount in a single round.
NewLimit’s approach, partial epigenetic reprogramming, sits at the frontier of this field. Rather than trying to fully reprogram cells back to a stem-cell-like state, which carries cancer risks, the company aims for a partial reset.
What this means for investors watching from the crypto side
The obvious question for crypto-native readers: does this have anything to do with blockchain? The short answer is no. NewLimit has no token, no protocol, and no on-chain component. This is a traditional biotech venture capital play.
Kleiner Perkins led the previous round, and the ability to raise $435 million in a single close suggests institutional conviction. The next 18 months, as NewLimit prepares its clinical trial applications, will determine whether that conviction was well placed.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
